Mature dendritic cells (DC) upregulate antigen presentation and co-stimulatory molecules on their surface as well as the production of inflammatory cytokines. This process can be induced by triggering receptors with cytokines, small molecules, or damage associated molecular patterns (DAMPs). It can be modulated by blocking the activity of molecules that normally inhibit DC maturation. Targeting uptake receptors that enable antigen cross-presentation can increase the ability of DC-based vaccines to trigger NK and CD8+ T cell cytolytic activity directed at the tumor cells.
| pDC Maturation Inducers | pDC Maturation Inhibitors |
| mDC Maturaton Inducers | mDC Maturation Inhibitors |
| pDC Maturation Inhibitors | |||
| A20/TNFAIP3 | DEC-205/CD205 | Fc epsilon RI alpha | Siglec-H |
| DCIR/CLEC4A | DLEC/CLEC4C/BDCA-2 | NKp44 Agonistic Antibodies | Wnt5a |
| mDC Maturation Inhibitors | ||
| A20/TNFAIP3 | IL-10 | Vitamin D Receptor Agonists |
| Bombesin | M-CSF | Additional Vitamin D Receptor Compounds |
| Bombesin Receptor Agonists | VEGF | |
| GDF-15 | VitD3 | |
